SEC Comment Letter for Calliditas Therapeutics AB (CIK 0001795579) — Jul 6, 2022
Calliditas Therapeutics AB (CIK 0001795579)
Date: July 6, 2022 · CIK: 0001795579 · Accession: 0000000000-22-007160
AI Filing Summary & Sentiment
File numbers found in text: 333-265881
Letter
United States securities and exchange commission logo July 6, 2022 Renée Aguiar-Lucander Chief Executive Officer Calliditas Therapeutics AB Kungsbron 1, D5 SE-111 22 Stockholm, Sweden Re:Calliditas Therapeutics AB Registration Statement on Form F-3 Filed June 28, 2022 File No. 333-265881 Dear Ms. Aguiar-Lucander: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Ada D. Sarmento at 202-551-3798 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Joshua A. Kaufman, Esq.
Show Raw Text
United States securities and exchange commission logo
July 6, 2022
Renée Aguiar-Lucander
Chief Executive Officer
Calliditas Therapeutics AB
Kungsbron 1, D5
SE-111 22
Stockholm, Sweden
Re:Calliditas Therapeutics AB
Registration Statement on Form F-3
Filed June 28, 2022
File No. 333-265881
Dear Ms. Aguiar-Lucander:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Ada D. Sarmento at 202-551-3798 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Joshua A. Kaufman, Esq.